These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 29351004)

  • 1. Duchenne muscular dystrophy: an updated review of common available therapies.
    Salmaninejad A; Valilou SF; Bayat H; Ebadi N; Daraei A; Yousefi M; Nesaei A; Mojarrad M
    Int J Neurosci; 2018 Sep; 128(9):854-864. PubMed ID: 29351004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
    Jarmin S; Kymalainen H; Popplewell L; Dickson G
    Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common therapeutic advances for Duchenne muscular dystrophy (DMD).
    Salmaninejad A; Jafari Abarghan Y; Bozorg Qomi S; Bayat H; Yousefi M; Azhdari S; Talebi S; Mojarrad M
    Int J Neurosci; 2021 Apr; 131(4):370-389. PubMed ID: 32241218
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
    Wong TWY; Cohn RD
    Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
    Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
    Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy.
    Bello L; Pegoraro E
    Acta Myol; 2016 Dec; 35(3):122-127. PubMed ID: 28484312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mutation-specific treatments for Duchenne muscular dystrophy].
    Matsuo M; Takeshima Y
    Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nonsense readthrough therapy for Duchenne muscular dystrophy].
    Takeshima Y
    Rinsho Shinkeigaku; 2014; 54(12):1074-6. PubMed ID: 25672712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy.
    D'Ambrosio ES; Mendell JR
    Neurotherapeutics; 2023 Oct; 20(6):1669-1681. PubMed ID: 37673849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical management of Duchenne muscular dystrophy: the state of the art.
    Messina S; Vita GL
    Neurol Sci; 2018 Nov; 39(11):1837-1845. PubMed ID: 30218397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic therapeutic approaches for Duchenne muscular dystrophy.
    Foster H; Popplewell L; Dickson G
    Hum Gene Ther; 2012 Jul; 23(7):676-87. PubMed ID: 22647146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.
    Mah JK
    Methods Mol Biol; 2018; 1687():3-17. PubMed ID: 29067652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From diagnosis to therapy in Duchenne muscular dystrophy.
    Babbs A; Chatzopoulou M; Edwards B; Squire SE; Wilkinson IVL; Wynne GM; Russell AJ; Davies KE
    Biochem Soc Trans; 2020 Jun; 48(3):813-821. PubMed ID: 32597486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy.
    Robinson-Hamm JN; Gersbach CA
    Hum Genet; 2016 Sep; 135(9):1029-40. PubMed ID: 27542949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy.
    Eslahi A; Alizadeh F; Avan A; Ferns GA; Moghbeli M; Reza Abbaszadegan M; Mojarrad M
    Gene; 2023 May; 867():147358. PubMed ID: 36914142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in genetic therapeutic strategies for Duchenne muscular dystrophy.
    Guiraud S; Chen H; Burns DT; Davies KE
    Exp Physiol; 2015 Dec; 100(12):1458-67. PubMed ID: 26140505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches.
    Shimizu-Motohashi Y; Komaki H; Motohashi N; Takeda S; Yokota T; Aoki Y
    J Pers Med; 2019 Jan; 9(1):. PubMed ID: 30621068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.